@ RUG BANK Browse +
`
`Search +
`
`Downloads
`
`About +
`
`Help+
`
`Contact Us
`
`| Search
`
`| Drugs
`
`¥ ci-
`
`| Spectra|Taxonomy|2 Comments1D Pharmacology Interactions | References | Trials Economics | Properties
`
`Sign up to get early access
`
`
`
`Biointeractions (24) BaemBaT UES]Umedageaaagoo
`
`Get DrugBank to go! The DrugBank app for iOS and Android is coming soon.
`
`Name
`
`Ibuprofen
`
`Accession Number
`
`Type
`
`Groups
`
`Description
`Structure
`
`DBO1050 (APRDOO372)
`Small Molecule
`
`Approved
`
`Ibuprofen, a propionicacid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
`ot
`
`ALE,
`
`|| mot | sor | sosor | pos | swnes | inch [ESUEEeae
`
`Synonyms
`(+-)}-2-(P-Isobutylphenyl) propionic acid
`
`(+-)-alpha-Methyl-4-(2-methylpropyl/benzeneacetic acid
`
`(+-)-Ibuprofen
`
`(+-)-P-lsobutylhydratropic acid
`
`(4-Isabutylphenyl)-alpha-methylacetic acid
`
`(RS)-ibuprofen
`
`2-(4-lsobutylphenyl)propanoic acid
`
`4-lsobutylhydratropic acid
`Adran
`
`Advil
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 001
`
`J |
`
`
`
`
`
`
`
`
`
`
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 001
`
`

`

`
`ID Pharmacology
`
`
`
`
`
`
`
`Interactions|References Trials
`
` uae
`
`
`alpha-(4-Isobutylphenyl)propionicacid
`alpha-{P-Isobutylphenyl)propionic acid
`Amibufen:
`
`
`
`
`
`
`
`
`
`Brufort
`Buburone
`Butylenin
`Dolgin
`Dolgirid
`
`
`Dolo-dolgit
`Ebufac
`Epobron
`Femadon
`
`
`
`Ibu-attritin
`Ibumetin
`
`Ibuprofen
`
`
`
`
`
`Ibuprophen:
`
`
`
`
`
`
`
`lebrufen
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 002
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 002
`
`

`

`
`
`ID
`2 Comments
`Interactions References|Trials|Economics
`Taxonomy
`Pharmacology
`Properties
`Spectra
`
`
`
`Search drugs
`
`Liptan
`
`Medipren
`Motrin
`
`Mynosedin
`Nobfen
`
`Nobgen
`
`Nuprin
`Nurofen
`
`P-lsobutylhydratropic Acid
`
`Para-lsobutylhydratropic Acid
`
`Pediaprofen
`Roidenin
`
`Rufen
`
`Seclodin
`
`Suspren
`Tabalon
`
`Trendar
`
`Urem
`
`ExternalIdentifiers
`
`Not Available
`
`Show) 10
`
`~ jentries
`
`Name
`
`Dosage
`
`Alti-ibuprofen Tab 600mg Tablet
`
`Caldolor
`
`Caldolor
`
`Ibuprofen Lysine
`it... nfnn FAN TA
`
`Solution
`
`Injection
`
`Solution
`Tabine
`
`Strength
`
`600 mg
`
`100 mz
`
`800
`mz/8mL
`
`Route
`
`Oral
`
`Labeller
`
`Altimed Pharma Inc.
`
`Intravenous Alveda Pharmaceuticals Inc
`
`Intravenous Cumberland Pharmaceuticals
`
`10 mg/mL
`onan
`
`Intravenous Prasco, Laboratories
`ent
`Thee
`
`Search
`
`Marketing
`Start
`
`1984-12-31
`
`2012-06-15
`
`2009-06-11
`
`Marketing
`End
`
`1999-09-17
`
`Not applicable
`
`Not applicable
`
`2016-04-14
`anor 4994
`
`Notapplicable
`ana a OF 4A
`
`8 A
`
`pproved
`Prescription
`Products
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 003
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 003
`
`

`

`ID Pharmacology|Interactions Trials|Economics Properties|Spectra Taxonomy|Torgets(@)References 2 Comments
`
`
`
`
`
`
`
`
`
`Search drugs
`Qa
`
`600 mg
`
`600 mg
`
`10 mg/mL
`
`600 mz
`
`600 mg
`
`5 mg/ml
`
`Ibuprofen-600 Tab
`600mg
`
`Motrin Tablets 600mg
`
`Neoprofen
`
`Novo-profen
`
`Nu-ibuprofen Tab 600mg
`Pedea
`
`Tablet
`
`Tablet
`
`Solution
`
`Tablet
`
`Tablet
`
`Injection,
`solution
`
`Showing 1 to 10 of 11 entries
`
`Show) 40
`
`~ entries
`
`Name
`
`Alivio
`
`Dosage
`Tablet
`
`Oral
`
`Oral
`
`Pro Doc Limitee
`
`1986-12-31
`
`2014-07-24
`
`Mcneil Consumer Healthcare Division Of Johnson & Johnson
`Inc
`
`1980-12-31
`
`2004-07-22
`
`il
`
`il
`
`Intravenous Recordati Rare Diseases Inc
`
`Oral
`
`Oral
`
`Teva
`
`Nu Pharm Inc
`
`Intravenous Orphan Europe S.A.RLL.
`
`Route
`
`Labeller
`
`Alivio Medical Products, Lic
`
`2006-04-13
`
`1985-12-31
`
`1993-12-31
`
`2004-07-29
`
`Not applicable
`
`Not applicable
`2012-09-04
`
`Not applicable
`
`Previous
`
`2
`
`Next
`
`Search
`
`Marketing
`Start
`
`2015-07-01
`
`Marketing
`End
`
`Not applicable
`
`Approved Generic
`Prescription
`Products
`
`
`
`Not applicable
`
`Not applicable
`
`Not applicable
`
`Not applicable
`
`Not applicable
`
`Not applicable
`
`Not applicable
`
`Not applicable
`
`Alivio
`
`Alivio
`
`Apo Ibuprofen Tab
`600mg
`Comfort Pac With
`Ibuprofen
`Ibu
`
`Ibu
`
`Ibu
`
`Ibu
`
`Ibu
`
`Tablet
`
`Tablet
`
`Tablet
`
`Kit
`
`Tablet
`
`Tablet
`
`Tablet
`
`Tablet
`
`Tablet
`
`Strength
`600
`mz/600mg
`800
`mz/800mg
`400
`mez/400meg
`
`600 mg
`
`800 mg/1
`
`800 mg/L
`
`600 mg/L
`
`600 mg/L
`
`400 mg/1
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`Oral
`
`Oral
`
`Oral
`Oral
`
`Alivio Medical Products, Lic
`
`Alivio Medical Products, Lic
`
`Apotex Corporation
`
`Pd Rx Pharmaceuticals, Inc.
`
`Golden State Medical Supply
`
`Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson
`Corporation
`
`Blenheim Pharmacal, Inc.
`
`Nu Care Pharmaceuticals,inc.
`Cardinal Health
`
`2015-07-01
`
`2015-07-01
`
`1984-12-31
`
`2012-09-06
`
`2014-04-22
`
`2009-06-17
`
`2012-03-23
`
`2008-11-20
`
`2009-07-20
`
`Not applicable
`
`4|3 |.| Be
`
`
`Previous
`2/3
`Showing 1 to 10 of 317 entries
`
`
`
`Sees Cisco
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 004
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 004
`
`

`

`ID
`
`Pharmacology
`
`Interactions
`
`References
`
`Trials
`
`Economics
`
`Properties
`
`Spectra
`
`Taxonomy
`Search drugs.
`
`
`
`2 Comments
`
`Approved Over the—show) in » entries a
`
`
`
`
`
`Counter Products
`:
`Marketing
`Marketing
`End
`Start
`
`Name
`
`Dosage
`
`Strength
`
`Route
`
`Labeller
`
`7 Select Childrens Ibuprofen
`
`Suspension
`
`100 m¢g/5mL_ Oral
`
`7 Select Ibuprofen
`
`7 Select Ibuprofen
`
`Tablet, coated
`
`200 mz/1
`
`Tablet, filmcoated
`
`200 ma/1
`
`Actiprofen - Caplet 200mg
`
`Tablet
`
`200 mg
`
`Advil
`
`Advil
`
`Advil
`
`Tablet, coated
`
`200 mg/t
`
`Capsule,liquid filled 200 mg/1
`
`Tablet, coated
`
`200 mg/1
`
`Ora
`
`Ora
`
`Ora
`
`Ora
`
`Ora
`
`Ora
`
`7 Eleven
`
`7 Eleven
`
`7 Eleven
`
`Bayer Inc Consumer Care
`
`Pfizer
`
`Pfizer
`
`Pfizer
`
`Lil’ Drug Store Products,Inc.
`
`2014-08-05
`
`Notapplicable =
`
`2014-05-13
`
`Noi applicable
`
`2014-08-07
`
`1996-12-31
`
`1984-05-16
`
`1995-04-10
`
`Notapplicable =
`1999-11-03
`el
`
`Notapplicable =
`
`Notapplicable
`
`==
`
`1984-05-18
`
`Notapplicable =
`
`2010-02-22
`
`Notapplicable =
`
`
`
`
`
`
`
`Notapplicable
`
`==
`
`Notapplicable =
`
`
`
`Tablet, coated
`
`Tablet, coated
`
`Tablet, coated
`
`
`
`200 mz/1
`
`200 mz/1
`
`256 ma/1
`
`Ora
`
`Ora
`
`Ora
`
`Pfizer
`
`Pfizer
`
`1984-05-18
`
`2013-07-08
`
`Advil
`
`Advil
`
`Advil
`
`Showing 1 to 10 of 957 entries
`
`Previous
`
`2|
`
`3)
`
`4
`
`3
`
`see
`
`96
`
`Next
`
`Unapproved/Other=show|40 « jentries seaireti
`
`
`
`Products @
`a
`
`Name
`
`Ibuprofen
`
`Dosage
`
`Tablet
`
`Showing 1 to 1 of 1 entries
`
`International Brands cya 49
`Name
`
`= leniies
`
`Act-3
`
`
`
`Actiprofen
`Adex
`
`Adran
`
`Aktren
`
`Alges-X
`
`Strength
`
`200 mg/i
`
`Route
`
`Oral
`
`Labeller
`
`Marketing Start
`
`Cardinal Health
`
`2011-06-02
`
`Marketing End
`
`Notapplicable
`
`Previous
`
`Next
`
`aah
`
`Company
`
`Healthcare Logistics
`
`Sterling Health
`Dexxon
`
`NotAvailable
`
`Bayer
`
`Axapharm
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 005
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 005
`
`

`

` Pharmacology |
`
`Interactions
`
`References
`
`‘Trials
`
`|
`
`|
`
`|
`Algoflex
`
`Algofren
`
`Alivium
`Artofen
`
`| Economics
`|
`
`Properties | Spectra | Taxonomy
`|
`_——
`
`2 Comments
`
`|
`
`Chinoin
`
`Intermed
`
`Bristol-Myers Squibb
`Teva
`
`Showing 1 to 10 of 116 entries 2/3) 4/5 |...|°42-|Previous Next
`
`
`
`
`
`
`
`hand spires
`
`Show] 10
`
`~ |entries
`
`search
`
`Name
`
`Labeller
`
`Ingredients
`
`10 Person Ansi Acetaminophen Acetylsalicylicacid|Bacitracin. Benzalkonium§Benzocaine|EthanolGenuineFirst Aid
`
`
`
`
`Ibuprofen§Lidocaine =Neomycin PolymyxinB Sulfate Water
`
`
`25 Person Ansi Acetaminophen|Acetylsalicylicacid|Bacitracin)Benzalkonium/Benzocaine»EthanolGenuineFirst Aid
`
`
`Ibuprofen|Isopropyl Alcohol|Lidocaine©Neomycin©PolymyxinB Sulfate(Water
`
`50 Person Ansi Acetaminophen§Acetylsalicylicacid|Bacitracin§Benzalkonium§BenzocaineGenuineFirst Aid Ethanol
`
`
`
`
`Ibuprofen§Isopropyl Alcohol|Lidocaine ~=Neomycin§PolymyxinB Sulfate©Water
`
`7 Select Ibuprofen PM
`
`7 Eleven
`
`Diphenhydramine
`
`Ibuprofen
`
`
`
`7-select Advil PM Diphenhydramine|IbuprofenLil’ Drug Store Products,Inc.
`
`
`
`
`
`
`
`Advil Allergy and Congestion Relief Chlorphenamine/IbuprofenNavajo Manuracturing Company Phenylephrine
`
`
`
`
`
`Advil Back Pain Ibuprofen=MethocarbamolPfizer Laboratories Div PfizerInc.
`
`
`
`Advil Allergy Sinus
`
`Pfizer
`
`Chlorphenamine
`
`Ibuprofen
`
`Pseudoephedrine
`
`
`
`Advil Cold & Flu Diphenhydramine.IbuprofenPfizer Laboratories Div PfizerInc.
`
`
`
`
`
`Advil Cold & Sinus Convenience Pack lbuprofen§Pseudoephedrine©PseudoephedrinePfizer Laboratories Div PfizerInc. Chlorphenamine Ibuprofen
`
`
`
`
`
`
`
`Showing 1 to 10 of 135 entries |.|4]Previous 2) 3) 4) 5 Next
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Salts
`
`Name/CAS
`Ibuprofen aluminum
`61054-06-6
`
`Structure
`1
`
`ue
`
`m
`
`We
`
`Properties
`®
`InChi Key: QAZIXAUMDFPQRW-UHFFFAOYSA-K
`* Monoisotopic Mass: 454.2299877
`e Average Mass: 454,543
`
`Ibuprofenlysine
`57469-77-9
`
`e
`
`e InChli Key: IHHXIUAEPKVVII-ZSCHIXSPSA-N
`® Monoisotopic Mass: 352.236207518
`
`DBSALTOO2285|
`;
`
`DBSALTOO1397
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 006
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 006
`
`

`

` TrialsInteractions|References Economics
`
`
`
`
`ID
`Pharmacology
`Properties
`Spectra
`
`Taxonomy 2 Comments
`
`Search drugs_
`
`Qa
`
`Ibuprofen aluminum
`61054-06-6
`
`i
`
`te
`
`ot
`
`ns
`
`InChli Key: QAZIXAUMDFPQRW-UHFFFAOYSA-K
`Monoisotopic Mass: 454.2299877
`Average Mass: 454.543
`
`Ibuprofenlysine
`57469-77-9
`
`Ibuprofen potassium
`79261-49-7
`
`Ibuprofen sodium
`527688-20-6
`
`ie
`
`bm
`
`me
`
`1
`
`InChl Key: IHHXIUAEPKVVII-ZSCHIXSPSA-N
`Monoisotopic Mass: 352.236207518
`Average Mass: 352.475
`
`InChl Key: XJIELUCTZEAQYGF-UHFFFAOYSA-M
`Monoisotopic Mass: 244.08656128
`Average Mass: 244.375
`
`InChl Key: VTIGPMVCGAVZLQI-UHFFFAOYSA-M
`Monoisotopic Mass: 264.13375344
`Average Mass: 264.297
`
`DBSALTO02285 |
`
`DBSALTOO1397
`
`DBSALTOO2Z264
`
`DBSALTOO1483
`
`Categories
`
`*® Acids, Carbocyclic
`« Analgesics
`Analgesics, Non-Narcotic
`Anti-Inflammatory Agents
`Anti-Inflammatory Agents, Non-Steroidal
`Antiinflammatory Products for Vaginal Administration
`Antirheumatic Agents
`Central Nervous System Agents
`Cyclooxygenase Inhibitors
`* Cytochrome P-450 CYP2C19 Substrates
`® Cytochrome P-450 CYP2C68 Substrates
`* Cytochrome P-450 CYP2C9 Inhibitors
`® Cytochrome P-450 CYP2C9 Substrates
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 007
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 007
`
`

`

`
`
`
`
`
`
`
`
`
`ID Pharmacology|Interactions Trials|Economics Spectra|Taxonomy|Targets(8)2 CommentsReferences Properties
`Search drugs.
`Qa
`
`2 ULYLCI OMe FP-45U CIP ZY SUSE ALES
`«* EnzymeInhibitors
`« Genito Urinary System and Sex Hormones
`« P-glycoprotein/ABCB1 Substrates
`e Peripheral Nervous System Agents
`« Phenylpropionates
`« Sensory System Agents
`
`UNII
`CAS number
`
`Weight
`
`WK2XY1100QM
`15687-27-1
`
`Average: 206.2808
`Monoisotopic: 206.135067982
`
`Chemical Formula
`
`CygHy,O5
`
`InChl Key
`
`InChl
`
`HEFNNWSXXWATRW-UHFFFAOYSA-N
`
`InChl=15/C13H1802/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
`
`IUPAC Name
`
`2-[4-(2-methylpropyl)pheny!]propanoic acid
`
`SMILES
`
`CC(C)CC1=CC=C(C=CAC(C)C(O}=O
`
`Eleciae)
`
`Indication
`
`For symptomatic treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis. May be used to treat mild to moderate pain and for the management of
`dysmenorrhea. May be used to reduce fever. Has been used with some successfor treating ankylosing spondylitis, gout and psoriatic arthritis. May reduce pain, fever and
`inflammation of pericarditis. May be used IV with opiates to relieve moderate to severe pain. Ibuprofen lysine may be used IV to treat patent ductus arteriosus (PDA) in
`premature neonates.
`
`Structured
`Indications @
`
`« Ankylosing Spondylitis (AS)
`« Cystic Fibrosis (CF)
`* Fevers
`* Gout
`*® Headaches
`* Juvenile Idiopathic Arthritis (JIA)
`« Menstrual cramp
`« Migraines
`e Patent Ductus Arteriosus (PDA)
`® Pericarditis
`e Primary Dysmenorrhea
`*® Rheumatoid Arthritis
`« Severe Pain
`e Mild Pain
`Moderate Pain
`Synovitis of osteoarthritis
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 008
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 008
`
`

`

`ID
` 2 Comments
`
`
`
`
`Pharmacology|Interactions Trials|Economics Properties|Spectra Taxonomy|Targets(8)References
`
`h drugs.
`Q
`SA rere oerere orn ro
`
`Pharmacodynamics
`
`Ibuprofenis a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has
`pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis.
`
`Mechanism ofaction
`
`The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the
`arachidonic acid pathway.Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in
`mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation,
`and subsequentheatdissipation.Inhibition of COX-1 is thought to cause someof the side effects of ibuprofen including Gl ulceration. Ibuprofen is administered as a racemic
`mixture. The R-enantiomer undergoes extensive interconversion to the $-enantiomerin vivo. The S-enantiomeris believed to be the more pharmacologically active
`enantiomer.
`
`Target
`
`Kind
`
`Pharmacological action
`
`Prostaglandin G/H synthase 2
`
`Protein FS
`
`Actions
`
`Peg
`
`Organism
`
`UniProt ID
`
`Human
`
`P35354C6
`
`details
`
`
`
`Prostaglandin G/H synthase 1 Protein|ves|Not Available Human P23219C details
`
`
`Apoptosis regulator Bcl-2
`Protein
`Human
`P10415 4
`details
`
`
`
`Thrombormedulin Protein§=[FE Human PO7204 G details
`
`
`Tissue-type plasminogen activator
`Protein
`Human
`poo7s0
`details
`
`Fatty acid-binding protein, intestinal
`
`Protein
`
`Peroxisomeproliferator-activated receptor gamma
`
`Protein re
`
`Cystic fibrosis transmembrane conductance regulator
`
`Protein
`
`flaw
`
`Perens
`
`Human
`
`Human
`
`Human
`
`P1271042
`
`P372310
`
`Pi35é69C
`
`details
`
`details
`
`details
`
`Related Articles
`
`Non-steroidal anti-inflammatory drugs andrisk of heart failure in four European countries:
`nested case-control study (~
`
`Nonopioid drugs for pain management
`
`Tho
`J Romano.
`MD.
`PhD et al
`
`|“
`
`Ibuprofen as effective as morphine for fracture pain in children, study shows.
`
`|“
`Taking the fifth (vital sign)
`al., Modern Mi
`
`
`Absorption
`
`Volume of
`distribution
`
`~ 80% absorbed from Gl tract
`Time to reach peak plasma concentration = 4/7 minutes (suspension), 62 minutes (chewable tablets), 120 minutes (conventional tablets)
`
`Not Available
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 009
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 009
`
`

`

`ID Pharmacology|Interactions Trials|Economics Properties|Spectra Taxonomy|Torgets(@)References 2 Comments
`
`
`
`
`
`
`
`
`
`Search drugs
`
`Protein binding
`Metabolism
`
`90-9996 to whole human plasma andsite II of purified albumin, binding appears to be saturable and becomes non-linear at concentrations exceeding 20 mcg/ml.
`
`R-enanatiomer undergoes extensive enantiomeric conversion (53-65%) to the more active S-enantiomerin vivo. Metablized by oxidation to 2 inactive metabolites: (+)-2
`[4°+{2-hydroxy-2-methylpropyl)phenyl]propionic acid and (+)-2-[4-(2-carboxypropyl)pheny!]propionic acid. Very small amounts of 1-hydroxyibuprofen and
`3-hydroxyibuprofen have been recovered from urine. Cytochrome P450 2C9 js the major catalyst in the formation of oxidative metabolites. Oxidative metabolites may be
`conjugated to glucuronideprior to excretion.
`
`Product
`
`Ibuprofen glucuronide
`
`[ioeTy
`
`2-Hydroxyibuprofen
`
`Enzymes
`
`>U
`
`DP-glucuronosyltransferase 1-1
`UDP-glucuronosyltransferase 1-3
`UDP-glucuronosyitransferase 1-9
`UDP-glucuronosyltransferase 2B4
`UDP-glucuronosyltransferase 2B7
`
`=>
`Cytochrome P450 2C8
`Cytochrome P450 2C9
`Cytochrome P450 2C19
`Cytochrome P450 344
`
`Substrate
`
`Ibuprofen
`
`Ibuprofen
`
`Ibuprofen
`3-Hydroxyibuprofen|Details|
`ytochrome P450 2C8
`Cytochrome P450 2C9
`
`>C
`
`1-hydroxyibuprofen
`
`Carboxy-ibuprofen
`
`erste
`
`peel E
`
`>N
`
`ot Available
`
`>C
`
`ytochrome P450 2C9
`
`Ibuprofen
`
`3-Hydroxyibuprofen
`
`Ibuprofen is rapidly metabolized and eliminated in the urine.
`2-4 hours
`
`Not Available
`
`Side effects: May cause peripheral edema andfluid retention. Use caution in patients with congestive heart failure or severe uncontrolled hypertension. May cause dyspepsia,
`heartburn, nausea, vomiting, anorexia, diarrhea, constipation, stomatitis, flatulence, bloating, epigastric pain, and abdominal pain. Peptic ulcer and Gl bleeding have been
`reported. May also cause dizziness, headache and nervousness. Acute renal failure accompanied by acute tubular necrosis has been reported.
`
`Most common symptoms of overdose are abdominal pain, nausea, vomiting, lethargy, vertigo, drowsiness (somnolence), dizziness and insomnia. Other symptomsof overdose
`include headache,loss of consciousness, tinnitus, CNS depression, convulsions and seizures. May rarely cause metabolic acidosis, abnormal hepatic function, hyperkalemia,
`stireS mirccern mir eeriednence 2 Mervinre cere fs ie Mb catsEEotome
`sc ne Avierire Hni to oearieenim DE bnEY
`
`Route ofelimination
`
`Halflife
`
`Clearance
`
`Toxicity
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 010
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 010
`
`

`

`
`
`
`
`ID Pharmacology|Interactions Trials|Economics Spectra|Taxonomy|Targets(8)Ei zynReferences Properties | 2 Comments
`
`
`
`
`
`
`
`
`Search drugs.
`Qa
`
`renal failure, dyspnea, respiratory depression, coma, acute renal failure, and apnea (primarily in very young pediatric patients).
`
`LDs9=1255meg/kglorally in mice)
`
`Affected organisms
`
`® Humans and other mammals
`
`Pathways
`
`SNP Mediated
`Effects
`
`SNP Mediated
`Adverse Drug
`Reactions
`
`Pathway
`Ibuprofen Action Pathway
`
`Ibuprofen Metabolism Pathway
`
`Not Available
`
`Not Available
`
`Category
`Drug action
`
`Drug metabolism
`
`SMPDBID
`SMPOO086
`
`SMPOOS90
`
`
`DrugInteractions
`Show! 40
`entries
`orci
`Drug
`
`Drug group
`
`Interaction
`
`16-Bromoepiandrosterone
`
`The risk or severity of adverse effects can be increased when Ibuprofen is combined with 16-
`Bromoepiandrosterone.
`
`19-norandrostenedione
`
`The risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-
`norandrostenedione.
`
`Investigational
`
`Experimental, Illicit
`
`4-Androstenedione
`
`5-androstenedione
`
`Abciximab
`
`Abiraterone
`
`Acebutolol
`
`Aceclofenac
`
`Acenocoumarol
`
`Acetaminophen
`
`The risk or severity of adverse effects can be increased when Ibuprofen is combined with 4-Androstenedione.
`
`Experimental, Illicit
`
`The risk or severity of adverse effects can be increased when Ibuprofen is combined with 5-androstenedione.
`
`Experimental, Illicit
`
`Ibuprofen may increase the anticoagulantactivities of Abciximab.
`
`The serum concentration of Ibuprofen can be increased whenit is combined with Abiraterone.
`
`Ibuprofen may decrease the antihypertensiveactivities of Acebutolol.
`
`The risk or severity of adverse effects can be increased when Ibuprofenis combined with Aceclofenac.
`
`Ibuprofen may increase the anticoagulantactivities of Acenocoumarol.
`
`The serum concentration of Ibuprofen can be increased whenit is combined with Acetaminophen.
`
`Approved
`
`Approved
`
`Approved
`
`Approved
`
`Approved
`
`Approved
`
`
`
`
`
`
`
`Showing 1 to 10 of 654 entries 3|4)5/]..|66°]Previous 2| Next
`
`
`
`Food Interactions
`
`* Avoid alcohol
`® Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 011
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 011
`
`

`

`* Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.
`* Take with food to reduce gastric irritation.
`
`
`
`Synthesis Reference—http://en.wikipedia.org/wiki/lbuprofen#Synthesis
`
`General References
`
`5]
`1. Zawada ET Jr: Renal consequences of nonsteroidal antiinflammatory drugs. Postgrad Med. 1982 May;7'1(5):223-30. [PubMed:7041104
`2. Townsend KP, Pratico D: Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005 Oct;19(12)-1592-601. [PubMed:16195348
`3. Chen dH,Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug useand the riskfor Parkinson's disease. Ann Neurol. 2005 Dec:58
`(6):963-7. [PubMed:16240369
`7]
`4. Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen
`acid. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):324-8. [PubMed:2777420
`5]
`>]
`5. Bergner T, Przybilla B: Photosensitization caused by ibuprofen. J Am Acad Dermatol. 1992 Jan;26(1)-114-6. [PubMed:1531054
`6. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li 5:4 molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi:
`10.1523/JNEUROSCI.5045-09.2010. [PubMed:20089905
`4]
`
`5]
`
`External Links
`
`Resource
`
`KEGG Drug
`
`KEGG Compound
`
`PubChem Compound
`PubChem Substance
`
`Link
`
`D00126
`
`c01588
`
`3672
`46507255
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 012
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 012
`
`

`

`
`
`Pharmacology|Interactions | References | Trials|Economics Properties|Spectra|Taxonomy
`|
`1D
`
`
`
`| Search dirugs_
`405U/ 29515
`
`FPuUDLneMm SuDsTance
`
`ChemSpider
`
`ChEBI
`ChEMBL
`
`Therapeutic Targets Database
`
`PharmGKB
`
`IUPHAR
`
`Guide to Pharmacology
`HET
`
`Drug Product Database
`
`RxList
`
`Drugs.com
`
`Wikipedia
`
`35440
`
`5855
`CHEMBL521@
`
`DAPOOO780
`
`PA449957
`
`27136
`
`2713
`IBP
`
`2609
`
`http://www.rxlist.com/cgi/generic/ibup.htm (
`
`http://www.drugs.com/ibuprofen.html
`
`Ibuprofen
`
`ATC Codes
`
`MO2AA13
`MO2AA — Antiinflammatory preparations, non-steroids for topical use
`MO2A4 — TOPICAL PRODUCTS FOR JOINT AND MUSCULARPAIN
`M02 — TOPICAL PRODUCTS FOR JOINT AND MUSCULARPAIN
`M — MUSCULO-SKELETAL SYSTEM
`RO2ZAX02
`RO2ZAX — Other throat preparations
`RO2A — THROAT PREPARATIONS
`RO2 — THROAT PREPARATIONS
`R— RESPIRATORY SYSTEM
`CO1EB16
`(CO1EB — Othercardiac preparations
`CO1E— OTHER CARDIAC PREPARATIONS
`C01 — CARDIAC THERAPY
`C— CARDIOVASCULAR SYSTEM
`MOLAES1
`MOAAE — Propionic acid derivatives
`MO1A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
`M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
`M — MUSCULO-SKELETAL SYSTEM
`MO1AEO01
`MOAE — Propionic acid derivatives
`MO1A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
`MO1 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
`M — MUSCULO-SKELETAL SYSTEM
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 013
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 013
`
`

`

`
`
`2 Comments
`
`
`ID Pharmacology|Interactions Trials|Economics Spectra|Taxonomy|Targets(8)EiReferences Properties
`Search drugs.
`Qa
`
`
`
`
`
`Wi WSLSRELE TAL OTSIEINI
`Go2CC01
`GO02CC — Antiinflammatory products for vaginal administration
`GO2C — OTHER GYNECOLOGICALS
`G02 — OTHER GYNECOLOGICALS
`G— GENITO URINARYSYSTEM AND SEX HORMONES
`
`AHFSCodes
`
`PDEEntries
`
`FDAlabel
`
`MSDS
`
`® 26:08.04.92
`
`Not Available
`
`Download (1.77 MB)
`
`Download (73.5 KB)
`
`Clinical Trials
`Clinical Trials @
`Shown
`v entries
`
`Search
`
`Phase
`0
`
`0
`
`0
`
`0
`
`al!
`
`al!
`
`al:
`
`if
`
`Al
`
`1
`
`Status
`Active Not
`Recruiting
`
`Completed
`
`Enrolling by
`Invitation
`
`Recruiting
`
`Active Not
`Recruiting
`
`Completed
`
`Completed
`
`Completed
`
`Completed
`
`Completed
`
`Purpose
`Basic Science
`
`Conditions
`Cancer, Breast
`
`Treatment
`
`Prevention
`
`Treatment
`
`Treatment
`
`Not Available
`
`Not Available
`
`Not Available
`
`Basic Science
`
`Primary Dysmenorrhea
`
`Hypertensive
`
`Ankle Fractures
`
`Spinal Cord Injuries (SCI)
`
`Autonomic Failure / Hypotension, Orthostatic
`
`Bioequivalence
`
`Healthy Volunteers
`
`Healthy Volunteer Study
`
`Basic Science
`
`Healthy Volunteers
`
`Count
`4
`
`i
`
`‘t
`
`i
`
`4
`
`1
`
`1
`
`5
`
`2
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`Showing 1 to 10 of 300 entries |-4|5 |...|30]Previous 2| 3 Next
`
`Pharmacoeconomics
`
`Manufacturers
`
`Not Available
`
`Packagers
`
`« Abbott Laboratories Ltd.
`« Actavis Group
`* Advanced Pharmaceutical Services Inc.
`® Aidarey Pharmaritticals | 1
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 014
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 014
`
`

`

`
`
`
`
`
`
`| Pharmacology|Interactions Trials|Economics Properties|SpectraID References Taxonomy 2 Comments
`
`
`
`
`
`
`
`| Search drugs._
`
`
`
`Aidarex Pharmacuticals LLC
`Altura Pharmaceuticals Inc.
`e Amerisource Health Services Corp.
`Amneal Pharmaceuticals
`* Apotheca Inc.
`« Apothecary Shop Wholesale
`« A-S Medication Solutions LLC
`« Ascend Laboratories LLC
`* Atlantic Biologicals Corporation
`« BASF Corp.
`e Bayer Healthcare
`*® Ben Venue Laboratories Inc.
`« Blenheim Pharmacal
`e Breckenridge Pharmaceuticals
`e Bryant Ranch Prepack
`* By Pharbita
`* Cardinal Health
`® Caremark LLC
`* Central Texas Community Health Centers
`® Centrix Pharmaceuticals
`« Chain Drug
`* Corepharma LLC
`« Coupler Enterprises Inc.
`*® Cumberland Pharmaceuticals
`« CVS Pharmacy
`* Darby Dental Supply Co.Inc.
`« Dept Health Central Pharmacy
`* DHHS Program Support Center Supply Service Center
`« Direct Dispensing Inc.
`« Dispensing Solutions
`* Diversified Healthcare Services Inc.
`* Doctor Reddys Laboratories Ltd.
`* DorxLLC
`*® Eckerd
`* Equaline Vitamins
`* Gm Pharmaceuticals Inc.
`* Golden State Medical Supply Inc.
`*® Greenstone LLC
`* Group Health Cooperative
`*® HandH Laboratories
`« HJ. Harkins Co.Inc.
`*® Hawthorn Pharmaceuticals
`« Heartland Repack Services LLC
`* HI! Moore Drug Exchange
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 015
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 015
`
`

`

`
`
`
`
`
`
`
`
`| Pharmacology|Interactions Trials|Economics Properties|SpectraID References
`
`
`
`Taxonomy Search drugs_
`
`® HI Moore Urug excnange
`*
`Imiren Pharmaceuticals Inc.
`«
`Innoviant Pharmacy Inc.
`*
`Ivax Pharmaceuticals
`* Kaiser Foundation Hospital
`* Keltman Pharmaceuticals Inc.
`*® Kowa Pharmaceuticals America Inc.
`« Lake Erie Medical and Surgical Supply
`« LeaderPharma
`* Legacy Pharmaceuticals Packaging LLC
`« Liberty Pharmaceuticals
`® LundbeckInc.
`« Major Pharmaceuticals
`* Mckesson Corp.
`*® McNeil Laboratories
`e Medicine Shop
`® Medique Products
`*® Medisca Inc.
`® Medvantx Inc.
`e Murfreesboro Pharmaceutical Nursing Supply
`*® Nucare Pharmaceuticals Inc.
`« Palmetto Pharmaceuticals Inc.
`« Par Pharmaceuticals
`« Particle Dynamics Co.
`« Patient First Corp.
`* PCALLC
`« PD-Rx Pharmaceuticals Inc.
`« Perrigo Co.
`* Pharmaceutical Association
`« Pharmaceutical Utilization Management Program VA Inc.
`*® Pharmacia Inc.
`* Pharmedix
`« Physicians Total Care Inc.
`® Poly Pharmaceuticals Inc.
`® Preferred Pharmaceuticals Inc.
`« Prepackage Specialists
`« Prepak SystemsInc.
`e Prescript Pharmaceuticals
`« Prescription Dispensing Service Inc.
`* Publix Super Markets
`*® Qualitest
`® Rebel Distributors Corp.
`* Redpharm Drug
`* Remedy Repack
`* Resource Optimization and Innovation LLC
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 016
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 016
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`ID Pharmacology|Interactions Trials|Economics Properties|SpectraReferences Taxonomy 2 Comments
`
`Search drugs_
`
`Rite Aid Corp.
`Sandhills Packaging Inc.
`Shanghai Ziyuan Pharmaceutical Co. Ltd.
`Shasun Chemicals & Drugs Ltd.
`Southwood Pharmaceuticals
`St Mary's Medical Park Pharmacy
`Stat Rx Usa
`Sunmark
`Talbert Medical Management Corp.
`Teva Pharmaceutical Industries Ltd.
`« UDL Laboratories
`Ultras Pharmaceuticals Inc.
`Va CmopDallas
`Wangard Labs Inc.
`Veratex Corp.
`Vintage Pharmaceuticals Inc.
`Vistapharm Inc.
`Walgreen Co.
`Watson Pharmaceuticals
`Wyeth Pharmaceuticals
`Mactdose Inc.
`
`Dosage forms
`
`Show) 10
`
`~ entries
`
`Form
`
`Tablet, extended release
`
`Capsule
`
`Capsule; kit
`
`Capsule
`
`Capsule
`
`Tablet, coated
`
`Tablet
`
`Tablet
`
`Tablet
`
`Tablet
`
`Route
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Oral
`
`Search
`
`Strength
`
`600 mg
`
`400 mg
`
`200 mg
`
`256 mg/1
`
`400 mg/400mg
`
`600 mg/600mzg
`
`800 mg/800mz
`
`300 mg
`
`
`
`
`
`
`
`Showing 1 to 10 of 70 entries se|| ae|BeetPrevious 2 es) |
`
`
`
`
`
`
`
`Prices
`
`Show] 10
`
`~ (entries
`
`Search
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 017
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 017
`
`

`

`
`
`
`
`
`
`
`
`
`ID Pharmacology|Interactions Trials|Economics Spectra|Taxonomy|Targets(8)| 2 CommentsReferences Properties
`Search drugs.
`Q
`
`aS
`
`» |entries
`Show) 10
`Unit description
`
`Neoprofen 20 mg/2 mlvial
`
`Caldolor 400 mg/4 mlvial
`
`Caldolor 600 mg/6 mlvial
`
`Nuprin arthritis patch
`
`Ibuprofen powder
`
`Nuprin muscle & joint patch
`
`Profen II 45-800 mg 12 Hourtablet
`
`Motrin 800 megtablet
`
`Advil allergy sinus caplet
`
`Ibu-drops 40 mg/ml suspension drops
`
`Search
`
`Cost
`
`304.5USD
`
`2.21U5D
`
`1.58USD
`
`1.41USD
`
`1.04U5D
`
`1.03USD
`
`0.69USD
`
`O.59USD
`
`0.5USD
`
`0.42USD
`
`Unit
`
`ml
`
`ml
`
`ml
`
`patch
`
`z
`
`patch
`
`tablet
`
`tablet
`
`caplet
`
`ml
`
`
`
`Showing 1 to 10 of 71 entries |.|]8|NextPrevious 2/3 /)4/5
`
`
`
`
`
`@ DrugBank doesnotsell nor buy drugs. Pricing informationis supplied for informational purposesonly.
`
`babes
`
`» jentries
`Show) 40
`Patent Number
`
`Pediatric Extension
`
`US5215755 4
`
`US62112466
`
`US6251426
`
`US6342530C
`
`USé6344479
`
`US6348216
`
`US56599531 6
`
`US6727286
`US7863287
`
`US8067033 CF
`
`tc
`
`fa
`
`tf
`
`tc
`
`tc
`
`ft
`
`Ct
`
`tc
`Cf
`
`ct
`
`Approved
`
`1993-06-01
`
`1999-06-10
`
`1998-06-25
`
`2000-11-14
`
`2001-03-20
`
`1997-06-10
`
`1997-06-10
`
`2001-11-27
`2007-02-28
`
`2006-07-18
`
`Search
`Expires (estimated)
`
`2010-06-01
`
`2019-06-10
`
`2018-06-25
`
`2020-11-14
`
`2021-03-20
`
`2017-06-10
`
`2017-06-10
`
`2021-11-27
`2027-02-28
`
`2026-07-18
`
`=
`
`=
`
`=
`
`=
`
`=
`
`a
`
`=
`
`=
`as
`
`a
`
`
`
`Showing 1 to 10 of 25 entries 2|3|NextPrevious
`
`
`
`
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 018
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 018
`
`

`

`
`
`
`
`ID Pharmacology|Interactions Trials|Economics Spectra|Taxonomy|Targets(8)Ei zynReferences Properties ) | 2Comments
`
`
`
`
`
`
`
`
`
`Search drugs.
`Q
`
`State
`
`Solid
`
`Experimental
`Properties
`
`Predicted Properties
`
`Property
`melting point
`
`water solubility
`
`logP
`
`logS
`
`Caco? permeability
`
`pKa
`
`property
`WaterSolubility
`
`logP
`
`logP
`
`logs
`
`
`
`pKa (Strongest Acidic)
`
`Physiological Charge
`
`Hydrogen Acceptor Count
`
`Hydrogen Donor Count
`
`Polar Surface Area
`Rotatable Bond Count
`
`Refractivity
`
`Polarizability
`Numberof Rings
`
`Bioavailability
`Rule of Five
`
`GhoseFilter
`
`Veber's Rule
`
`MDDR-like Rule
`
`Value
`75-775
`
`Source
`U.S. Patent 3,228,831 U.S. Patent 3,385,886
`
`21 mg/L(at 25 °C)
`
`YALKOWSKY,SH & DANNENFELSER,RM (1992)
`
`3.97
`
`“3.99
`
`-4,.38
`
`4.91
`
`AVDEEF,A (1997)
`
`ADMEResearch, USCD
`
`ADMEResearch, USCD
`
`SANGSTER(1994)
`
`Value
`0.0684 mg/mL
`
`3.5
`
`3.64
`
`“3.5
`
`4.85
`
`-1
`
`2
`
`1
`
`37.3 A?
`4
`
`60.73 m2-mol+
`
`23.76 Az
`i
`
`i
`Yes
`
`Yes
`
`Yes
`
`Yes
`
`Source
`ALOGPS
`
`ALOGPS
`
`ChemAxon
`
`ALOGPS
`
`ChemAxon
`
`ChemAxon
`
`ChemAxon
`
`ChemAxon
`
`ChemAxon
`ChemAxon
`
`ChemAxon
`
`ChemAxon
`ChemAxon
`
`ChemAxon
`ChemAxon
`
`ChemAxon
`
`ChemAxon
`
`ChemAxon
`
`Predicted ADMET
`features
`
`Property
`
`Value
`
`Probability
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 019
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 019
`
`

`

`ID
`2 Comments
`Interactions|References|Trials|Economics
`
`Pharmacology
`
`Spectra Taxonomy|Targets(8)E
`Search drugs.
`Q
`
`Probability
`0.9927
`
`0.9619
`
`0.6866
`
`0.759
`
`0.9705
`
`0.9323
`
`0.9323
`
`0.7594
`
`0.9116
`
`0.6877
`
`0.9045
`
`0.9305
`
`0.9231
`
`0.9861
`
`0.9655
`
`0.9691
`
`0.9894
`
`0.5553
`
`0.5142
`
`Not applicable
`
`0.9719
`
`0.9734
`
`Value
`i"
`
`i E
`
`e N
`
`on-substrate
`
`Non-inhibitor
`
`Non-inhibitor
`
`Non-inhibitor
`
`Non-substrate
`
`Non-substrate
`
`Non-substrate
`
`Non-inhibitor
`
`Non-inhibitor
`
`Non-inhibitor
`
`Non-inhibitor
`
`Non-inhibitor
`
`Low CYPInhibitory Promiscuity
`Non AMEStoxic
`
`Carcinogens
`
`Ready biodegradable
`
`2.3092 LD50, mol/kg
`Weakinhibitor
`
`Non-inhibitor
`
`Predicted ADMET
`features
`
`Property
`
`Human Intestinal Absorption
`Blood Brain Barrier
`
`Caco-? permeable
`
`P-glycoprotein substrate
`
`P-glycoprotein inhibitor |
`
`P-glycoprotein inhibitorIl
`
`Renal organic cation transporter
`CYP450 2C9 substrate
`
`CYP450 2D6 substrate
`
`CYP450 3A4 substrate
`
`CYP450 1A2 substrate
`
`CYP450 2C9inhibitor
`
`CYP450 2D6inhibitor
`
`CYP450 2C19 inhibitor
`
`CYP450 3A4 inhibitor
`
`CYP450inhibitory promiscuity
`Ames test
`
`Carcinogenicity
`
`Biodegradation
`
`Rat acute toxicity
`
`hERGinhibition (predictor |)
`
`hERGinhibition (predictor |!)
`
`@ ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 (“)
`
` bea
`Mass Spec (NIST)
`
`Spectra
`
`Download (11.4 KB)
`
`Spectrum
`Type
`
`GC-MS
`
`Description
`
`Splash Key
`
`GC-MS Spectrum - GC-EI-TOF (PegasusIII TOF-MS system, Leco; GC 6890, Agilent
`Technologies) [1 TMS)
`
`splash10-02t9-1910000000-
`23f448d7he7dSsce35Aa?
`
`View in MoNA
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 020
`
`Par Pharm., Inc.
`Exhibit 1062
`Page 020
`
`

`

`
`
`
`
`
`2 Comments
`
`
`
`ID Pharmacology|Interactions Trials|Economics Properties|Spectra Taxonomy|Targets(8)References
`Search drugs.
`Qa
`
`GC-MS
`
`GC-MS
`
`GC-MS
`
`GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6390, Agilent
`Technologies) (1 TMS)
`
`GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6390, Agilent
`Technologies) (1 TMS}
`
`GC-MS Spectrum - GC-EI-TOF (Pegasus IIl TOF-MS5 system, Leco; GC 6390, Agilent
`Technologies) (1 TMS)
`
`LC-MS/MS
`
`LC-MS/MS Spectrum - Quattro_QQ0 10V, N/A (Annotated)
`
`LC-MS/MS
`
`LC-MS/MS Spectrum - Quattro_QQ0 25V, N/A (Annotated)
`
`LC-MS/MS
`
`LC-MS/MS Spectrum - El-B (HITACHI RMU-6E), Positive
`
`MS
`
`1D NMR
`
`1DNMR
`
`1D NMR
`
`2D NMR
`
`Mass Spectrum (Electron lonization)
`
`1THNMR Spectrum
`
`IH NMR Spectrum
`
`13C NMR Spectrum
`
`[1H,13C] 2D NMR Spectrum
`
`splashi0-02t9-1910000000-
`23f446d7be7d5cc35